[1] DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015:Convergence of incidence rates between black and white women[J]. CA Cancer J Clin, 2016,66(1):31-42. [2] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014,15(7):e279-e289. [3] Bertucci F, Birnbaum D. Distant metastasis:not out of reach any more[J]. J Biol, 2009,8(3):28. [4] Kubo Y, Naito T, Mori K, et al. Skeletal muscle loss and prognosis of breast cancer patients[J]. Support Care Cancer, 2017,25(7):2221-2227. [5] Gnant M, Harbeck N, Thomssen C. St. Gallen/Vienna 2017:A brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment[J]. Breast Care(Basel), 2017,12(2):102-107. [6] Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy[J]. Nat Nanotechnol, 2007,2(12):751-760. [7] Wang DG, Wang TT, Xu ZA, et al. Cooperative treatment of metastatic breast cancer using host-guest nanoplatform coloaded with docetaxel and siRNA[J]. Small, 2016,12(4):488-498. [8] Yu HJ, Guo CY, Feng B, et al. Triple-layered pH-responsive micelleplexes loaded with siRNA and cisplatin prodrug for NF-Kappa B targeted treatment of metastatic breast cancer[J]. Theranostics, 2016,6(1):14-27. [9] Zhao YQ, Zhang T, Duan SF, et al. CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy[J]. Nanomedicine, 2014,10(6):1221-1230. [10] Camacho KM, Kumar S, Menegatti S, et al. Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid[J]. J Control Release, 2015,210:198-207. [11] Bano F, Banerji S, Howarth M, et al. A single molecule assay to probe monovalent and multivalent bonds between hyaluronan and its key leukocyte receptor CD44 under force[J]. Sci Rep, 2016, 6:34176. [12] Ahmed S, Annu, Chaudhry SA, et al. A review on biogenic synthesis of ZnO nanoparticles using plant extracts and microbes:A prospect towards green chemistry[J]. J Photochem Photobiol B Biol, 2017,166:272-284. [13] 谷学源. 以顺铂为交联剂基于透明质酸为载体的纳米药物对CD44高表达的乳腺癌的治疗的研究[D]. 沈阳:中国医科大学, 2016. [14] Guo H, Xu W, Chen J, et al. Positively charged polypeptide nanogel enhances mucoadhesion and penetrability of 10-hydroxycamptothecin in orthotopic bladder carcinoma[J]. J Control Release, 2017,259:136-148. [15] Schmid D, Park CG, Hartl CA, et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity[J]. Nat Commun, 2017,8(1):1747. [16] Rejinold NS, Baby T, Chennazhi KP, et al. Multi drug loaded thermo-responsive fibrinogen-graft-poly(N-vinyl Caprolactam) nanogels for breast cancer drug delivery[J]. J Biomed Nanotechnol, 2015,11(3):392-402. [17] Kolter M, Ott M, Hauer C, et al. Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in human whole blood and in vivo[J]. J Control Release, 2015, 197:165-179. [18] Oh SS, Lee BF, Leibfarth FA, et al. Synthetic aptamer-polymer hybrid constructs for programmed drug delivery into specific target cells[J]. J Am Chem Soc, 2014, 136(42):15010-15015. [19] Ansari L, Shiehzadeh F, Taherzadeh Z, et al. The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer:A systematic review of clinical trials[J]. Cancer Gene Ther, 2017,24(5):189-193. [20] Florea AM, Busselberg D. Cisplatin as an anti-tumor drug:cellular mechanisms of activity, drug resistance and induced side effects[J]. Cancers (Basel), 2011,3(1):1351-1371. [21] Pezeshki Z, Maleki M, Talebi A, et al. Age and gender related renal side effects of cisplatin in animal model[J]. Asian Pac J Cancer Prev, 2017,18(6):1703-1705. [22] Yu PF, Huang Y, Xu CL, et al. Downregulation of CXCL12 in mesenchymal stromal cells by TGFbeta promotes breast cancer metastasis[J]. Oncogene, 2017,36(6):840-849. [23] Pu X, Storr SJ, Zhang Y, et al. Caspase-3 and caspase-8 expression in breast cancer:caspase-3 is associated with survival[J]. Apoptosis, 2017,22(3):357-368. |